| 3.54 0.08 (2.31%) | 11-07 11:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.69  |
1-year : | 6.82 |
| Resists | First : | 4.87 |
Second : | 5.84 |
| Pivot price | 4.1 |
|||
| Supports | First : | 3.31 |
Second : | 2.76 |
| MAs | MA(5) : | 3.83 |
MA(20) : | 4.37 |
| MA(100) : | 2.82  |
MA(250) : | 2.02 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.6 |
D(3) : | 14.6 |
| RSI | RSI(14): 38.1 |
|||
| 52-week | High : | 5.84 | Low : | 0.96 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ENTO ] has closed below the lower bollinger band by 6.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.11 - 4.13 | 4.13 - 4.15 |
| Low: | 3.35 - 3.38 | 3.38 - 3.4 |
| Close: | 3.43 - 3.46 | 3.46 - 3.5 |
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Fri, 07 Nov 2025
Entero Regains Nasdaq Compliance With Grid AI Acquisition - The State Journal-Register
Thu, 06 Nov 2025
Entero Therapeutics Board Appointment Waiver by GridAI - TradingView
Thu, 06 Nov 2025
Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid - Lexington Herald Leader
Thu, 06 Nov 2025
Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid - standard-journal.com
Thu, 06 Nov 2025
Entero (NASDAQ: ENTO) signs LOI to integrate LV Grid into Grid AI in $10–20B market - Stock Titan
Wed, 05 Nov 2025
Entero Regains Nasdaq Compliance With Grid AI Acquisition - Palm Beach Daily News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 5.7 (%) |
| Held by Institutions | 2 (%) |
| Shares Short | 167 (K) |
| Shares Short P.Month | 76 (K) |
| EPS | -11.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.97 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -3.4 % |
| Return on Equity (ttm) | -24.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 11 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | -0.87 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|